DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced a proposed registered public offering of its common stock and warrants to purchase common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering…
Read More
An early report on the molecular subtyping of muscle-invasive bladder cancer (MIBC) by gene expression suggested that response to neoadjuvant chemotherapy (NAC) varies by subtype. To investigate the ability of molecular subtypes to predict pathological downstaging and survival after NAC. Whole transcriptome profiling was performed on pre-NAC transurethral resection specimens from 343 patients with MIBC. Samples were classified according to four published…
Read More
Researchers have obtained an unprecedented view of the ‘ballistic’ weaponry of planktonic microbes, including one that can fire projectiles as if wielding a Gatling gun. “We think of plankton as the tiny alphabet soup of the ocean, floating around passively while larger organisms eat it,” says biologist Gregory Gavelis, who lead the study while a researcher at the University of…
Read More
Hundreds of people are expected to march in Vancouver this Saturday to celebrate the role of science in our lives and support evidence-based government policy. Communications officer Kristina Charania says the idea for the march started in January in response to U.S. President Donald Trump’s administration deleting nearly all mentions of climate change off the White House website. Climate change received fairly high…
Read More
Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced that it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) and a preliminary prospectus with the securities regulatory authorities in each…
Read More

Two Stories of Transition Success

Success is such an arbitrary measure. “My main advice is to create your own definition of success”, recommends Grace Lee, a transition expert. “Very often we let everyone else define what it means to be successful: a great career, a family… In our field, articles became the currency of success, but that is not what defines you”. Grace metamorphosed a…
Read More
The panel charged with reviewing the federal government’s support of fundamental science released its final report on April 10, laying out a multi-year strategy that includes greater investment in independent investigator-led projects, better coordination between the four core research funding agencies and the creation of an oversight body called the National Advisory Council on Research and Innovation. The panel also…
Read More
My PhD journey is coming to its end and I am considering a non-academic career. Looking at job descriptions, I know I tick the box marked ‘strong analytical and problem-solving skills.’ However, there are other boxes to consider: ‘Strong time and project management skills.’ ‘A team player with a proven track record of collaborations.’ ‘The ability to communicate clearly and…
Read More
Dr. Catalina Lopez-Correa is the Chief Scientific Officer (CSO) of Genome BC and former CSO of Genome Quebec. Formally trained as both a medical physician and scientific researcher, her background in biotech, pharmacy, and corporate America allowed her to travel the world while preparing her for her current position. We sat down with Dr. Lopez-Correa to discuss her journey from…
Read More